pharma · Peripheral Artery Disease · Muscle-Invasive Bladder Carcinoma
Blackmores Institute
Blackmores Limited
Blackmores Institute is a pharma organization headquartered in Warriewood, AU. Primary therapeutic focus areas include Peripheral Artery Disease, Muscle-Invasive Bladder Carcinoma, Therapeutic Equivalency, Solid Tumor, A
20 Jubilee Ave, Warriewood, New South Wales 2102, AU HQ
2012 Founded
27 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 20 Jubilee Ave, Warriewood, New South Wales 2102, AU
- Founded
- 2012
- Employees
- 27
- Programs
- 17
- Drugs
- 24
- Patents
- 38
silevertinib in combination with temozolomide
Phase 2 · small molecule · Glioblastoma (GBM)
silevertinib in combination with temozolomide for Glioblastoma (GBM) is a Phase 2 program (small_molecule) at Blackmores Limited with 1 ClinicalTrials.gov record(s).
Internal code BDTX-1535-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Blackmores Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Glioblastoma (GBM)
- Status
- active
- Trials
- 1